The objective was to evaluate the effectiveness and safety, with a specific focus on cardiovascular safety, of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, compared to insulin glargine in adults with type 2 diabetes and a high risk of cardiovascular events who have not achieved adequate control with oral glucose-lowering medications.This phase 3 study was conducted at 187 sites across 14 countries on five continents
I have a related blog on this topic
Provides immune system support: It helps regulate white blood cell activity, boost immune function, and protect against illness
Using the pen beyond this window increases your risk of infection
Mocelin R, Marcon M, Dambros S, Mattos J, Sachett A, Siebel AM, et al